根据一份提交给美国证券交易委员会的文件，Liminatus Pharma公司的股东——Innocsai成员，将获得一项总额可观的补偿方案。该方案的核心内容包括：以每股0.20美元的价格，获得总计16亿股的公司股份。此外，作为协议的一部分，这些成员还将获得相当于其总股份价值20%的或然价值权。这一安排旨在为特定股东群体提供额外的价值补偿与潜在收益保障。
根据一份提交给美国证券交易委员会的文件，Liminatus Pharma公司的股东——Innocsai成员，将获得一项总额可观的补偿方案。该方案的核心内容包括：以每股0.20美元的价格，获得总计16亿股的公司股份。此外，作为协议的一部分，这些成员还将获得相当于其总股份价值20%的或然价值权。这一安排旨在为特定股东群体提供额外的价值补偿与潜在收益保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.